Erratum to: Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen: Eine systematische übersichtsarbeit von randomisierten, kontrollierten Studien (Der Schmerz, (2016), 30, 1, (62-88), 10.1007/s00482-015-0089-y);Erratum to: Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies (Der Schmerz, (2016), 30, 1, (62-88), 10.1007/s00482-015-0089-y);Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies;Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden bei neuropathischen Schmerzsyndromen: Eine systematische Übersichtsarbeit von randomisierten, kontrollierten Studien

Schmerz

Volumn 30, Issue 1, 2016, Pages 62-88

  Petzke, F ^a   Enax Krumova, E K ^b   Hauser W ^c,d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c KLINIKUM SAARBRÜCKEN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cannabidiol; Cannabis; Dronabinol; Nabilone; Tetrahydrocannabinol

Indexed keywords

CANNABINOID; DRONABINOL; MEDICAL CANNABIS; NABILONE; NABIXIMOLS; PLACEBO;

ANALGESIA; ARTICLE; ATTRIBUTABLE RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MENTAL DISEASE; NEUROPATHIC PAIN; PAIN INTENSITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; NEURALGIA;

CANNABINOIDS; CHRONIC PAIN; HUMANS; NEURALGIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84958637530     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-017-0242-x     Document Type: Erratum

References (32)

1. Treede RD, Jensen TS, Campbell JN et al (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70:1630–1635
2. Jensen TS, Baron R, Haanpää M et al (2011) A new definition of neuropathic pain. Pain 152:2204–2205
3. Finnerup NB, Scholz J, Attal N et al (2013) Neuropathic pain needs systematic classification. Eur J Pain 17:953–956
4. Helfert SM, Reimer M, Höper J et al (2015) Individualized pharmacological treatment of neuropathic pain. Clin Pharmacol Ther 97:135–142
5. Van Hecke O, Austin SK, Khan RA et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155:654–662
6. Finnerup NB, Attal N, Haroutounian S et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–173
7. National Institute for Health and Care Excellence (NICE) (2013) Neuropathic pain – pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. http://www.nice.org.uk/guidance/cg173. Zugegriffen: 19. Oktober 2014
8. Bundesgesundheitsministerium (2015) Referentenentwurf für eine Fünfundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften. http://www.bundesgesundheitsministerium.de/fileadmin/fa_redaktion_bak/pdf_gesetze/laufend/btmaendVO25-refentwurf.pdf. Zugegriffen: 6. November 2015
9. Moulin DE, Boulanger A, Clarke AJ et al (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 19:328–335
10. Koppel BS, Brust JC, Fife T et al (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82:1556–1563
11. Andreae MH, Carter GM, Shaparin N et al (2015) Inhaled cannabis for chronic neuropathic pain: an individual patient data meta-analysis. J Pain 16:1221–1232. doi:10.1016/j.jpain.2015.07.009
12. Boychuk DG, Goddard G, Mauro G et al (2015) The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. J Oral Facial Pain Headache 29:7–14
13. Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:735–744
14. Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473
15. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34
16. Dworkin RH, Turk DC, Wyrwich KW et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105–121
17. Higgins JPT, Green S (Hrsg) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, London. http://www.cochrane-handbook.org
18. International Association for Cannabinoid Medicines (IACM) http://www.cannabis-med.org/?lng=en
19. Baron R, Binder A (2004) How neuropathic is sciatica? The mixed pain concept. Orthopade 33:568–75
20. Furukawa TA, Cipriani A, Barbui C et al (2005) Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 20:49–52
21. Moore RA, Eccleston C, Derry S et al; ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors (2010) „Evidence“ in chronic pain—establishing best practice in the reporting of systematic reviews. Pain 150:386–389
22. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA). http://www.meddra.org. Zugegriffen: 1. Oktober 2015
23. The Nordic Cochrane Centre (2014) Review Manager (RevMan) [Computer program]. Version 5.3. The Cochrane Collaboration, Copenhagen
24. Moore RA, Barden J, Derry S, McQuay HJ (2008) Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA (Hrsg) Systematic reviews in pain research: methodology refined. IASP Press, Seattle, S 15–24
25. Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale
26. Fayers PM, Hays RD (2014) Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality Life Res 23:1–4
27. Häuser W, Klose P, Welsch P et al (2015a) Methodenreport der aktualisierten Leitlinie „Langzeitanwendung von Opioiden bei nicht-tumorbedingten Schmerzen – LONTS“. Schmerz 29:8–34
28. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29:2068–2079
29. Hoggart B, Ratcliffe S, Ehler E et al (2015) A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol 262:27–40
30. Zajicek JP, Sanders HP, Wright DE et al (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76:1664–1669
31. Mulla SM, Buckley DN, Moulin DE et al (2014) Management of chronic neuropathic pain: a protocol for a multiple treatment comparison meta-analysis of randomised controlled trials. BMJ Open 4:e006112
32. Häuser W, Bock F, Engeser P et al (2015) Empfehlungen der aktualisierten Leitlinie LONTS. Schmerz 29:109–130